US Patent 10,772,897 Scope and Claims for Ulipristal Acetate Contraception After Unprotected Intercourse (120 Hours)
US 10,772,897 is directed to a time-windowed, dose-quantified method for emergency contraception using ulipristal acetate tablets containing 20 mg to 30 mg, administered within 120 hours after unprotected intercourse. The claim set narrows by (i) a secondary time window (more than 72 up to 120 hours), (ii) repeated dosing at least twice in a menstrual cycle, and (iii) oral, immediate-release tablet formats. The practical implication for freedom-to-operate is that any US activity (including marketing, manufacturing, or prescribing inducement) that practices the claimed clinical sequence, dose range, and timing window risks infringement unless it is outside all asserted claim elements.
What does US Patent 10,772,897 claim for ulipristal acetate emergency contraception?
US 10,772,897 claims are method claims. Each independent claim element is a combination of: (1) contraceptive purpose, (2) ulipristal acetate tablet with a specified dose range, (3) timing relative to unprotected intercourse, and (4) route/dosage form limitations for dependent claims.
Claim 1: Core protected act (dose + timing + emergency contraception)
Claim 1
- Method for contraception
- Administering a tablet comprising 20 mg to 30 mg of ulipristal acetate
- To a woman
- Within 120 hours after unprotected intercourse
This is the spine of the estate: a broad method covering emergency contraception use with ulipristal acetate tablets in a defined dose band, with a hard maximum time window of 120 hours.
Claim 1’s functional boundary
- “Within 120 hours” covers dosing at any time after unprotected intercourse as long as it is not beyond 120 hours.
- The dose range is a numeric constraint. It is not simply “ulipristal acetate”; it is ulipristal acetate at 20 to 30 mg in the administered tablet.
- The “method for contraception” ties the activity to the intended clinical use. In infringement practice, proving that the administration is for emergency contraception is typically the critical intent/use element for method-of-use claims.
Claim 2: Secondary timing carve-out (72 to 120 hours)
Claim 2
- Method of claim 1
- Tablet administered more than 72 hours and up to 120 hours after unprotected intercourse
Claim 2 narrows the claim 1 time window, capturing a later administration window that is often a target for differentiation between emergency contraception products and regimens.
Claim 3: Menstrual cycle repetition limitation
Claim 3
- Method of claim 1
- Administration repeated at least twice during a menstrual cycle
This introduces a regimen element beyond a single-dose emergency contraception event. It can cover schedules where ulipristal acetate is administered multiple times in one menstrual cycle, assuming the administrations fall within the claimed timing relationship to unprotected intercourse.
Claim 4: Oral tablet limitation
Claim 4
This excludes non-oral routes from coverage for the dependent branch.
Claim 5: Immediate-release oral tablet limitation
Claim 5
- Tablet is an immediate-release oral tablet
This excludes extended-release or modified-release dosage forms from coverage for the dependent branch.
How broad is the claim scope: what does infringement likely turn on?
US method claims typically require proof that the accused conduct contains every limitation. For 10,772,897, infringement exposure concentrates on whether an entity’s product and labeling/practice fit the defined regimen.
Scope drivers (high-sensitivity limitations)
-
Dose range: 20 mg to 30 mg ulipristal acetate
- A tablet outside this range is outside claim 1’s dose limitation.
- A formulation delivering the same amount of ulipristal acetate but with different pharmacokinetic release may still fit claim 1, unless dependent claims (immediate-release) are asserted.
-
Time window: within 120 hours
- Products that are labeled or practiced only up to a shorter maximum time (for example, ≤72 hours) can fall outside claim 1’s time limitation if practice does not extend into 72–120 hours.
-
Regimen repetition: at least twice in a menstrual cycle
- This limitation narrows claim 3 exposure to regimens with multiple administrations per cycle.
-
Dosage form: immediate-release oral
- This matters only for claims 4 and 5. Claim 1 does not require immediate-release, but claim scope can expand if the accused product uses immediate-release oral tablets.
“Method for contraception” as the use element
A method claim requires that the administration be for emergency contraception. In practice, the strongest enforcement record is usually built from product labeling, physician instructions, promotional materials, and real-world use consistent with those materials.
Which dependent claim restrictions matter most for design-around?
Design-around analysis typically starts with the limitations that are easiest to change: dose, maximum timing, route, and release characteristics.
Dose design-around
- Avoid 20–30 mg tablets: using doses outside the range reduces risk for claim 1 and its dependent claims.
Timing design-around
- Avoid practice beyond 72 hours: claim 2 is only “more than 72 up to 120 hours.” If a program only supports use up to 72 hours, claim 2 exposure can be reduced.
- Claim 1, however, still reaches “within 120 hours,” so narrower labeling must ensure no intended or induced practice into 72–120.
Dosage form and release design-around
- Non-immediate-release formulations can reduce exposure to claim 5, and possibly claim 4 if not oral.
- Claim 1 remains broader on release type; a non-immediate-release oral dosage can still infringe claim 1 if it administers 20–30 mg ulipristal acetate within 120 hours.
Regimen design-around
- For claim 3, avoiding repeated administrations within a menstrual cycle reduces risk if the conduct never meets “at least twice during a menstrual cycle.”
How long does US 10,772,897 remain enforceable and when does exclusivity end?
A precise exclusivity/expiration analysis requires the patent’s USPTO data (filing date, priority, and term adjustments) and any patent term adjustment (PTA). The only information provided here is the claim text, which is insufficient to determine:
- patent term end date,
- PTA/PTAB effects,
- any terminal disclaimer,
- or alignment with Orange Book-listed exclusivities for any specific FDA product.
No enforceability timeline can be stated from the claim excerpt alone.
What is the likely patent estate around ulipristal acetate emergency contraception in the US?
The surrounding patent landscape for ulipristal acetate emergency contraception commonly includes:
- composition-of-matter claims (ulipristal acetate),
- formulation claims (tablet composition, excipient systems, particle engineering),
- method-of-use claims (timing windows, dosing schedules),
- and possibly additional regimen-based claims for specific intervals or repeat dosing.
For 10,772,897 specifically, the claim set indicates method-of-use coverage anchored on:
- dose range (20–30 mg),
- time window (≤120 hours; with specific subclass 72–120),
- repeat dosing (at least twice per cycle),
- and immediate-release oral.
This positions the patent as a regulator of clinical claims, labeling claims, and inducement for emergency contraception regimens, not primarily a protection for the active ingredient chemistry.
How does this patent compare with typical competing emergency contraception intellectual property?
Emergency contraception products in the US often cluster around different approaches:
- ulipristal acetate vs levonorgestrel vs other regimens,
- different allowed maximum time windows,
- and different dosing schedules or repeat dosing protocols.
Strategic differentiation likely targeted by 10,772,897
- A hard 120-hour ceiling with a 20–30 mg dose band is a claimable commercial/legal boundary that can distinguish regimens that are marketed as effective only up to a shorter horizon.
- Claim 2’s “more than 72 up to 120” targets later administration, which can correspond to competitor labeling differences.
- Claim 3 targets a non-single-dose approach: multiple administrations within a menstrual cycle.
Practical competitive risk
- If a competitor’s product is ulipristal acetate in the same dose range and is promoted or practiced for administration within 120 hours, claim 1 exposure is direct.
- If promoted particularly for use after 72 hours, claim 2 exposure increases.
- If promoted for repeat dosing per cycle, claim 3 exposure rises.
What generic entry risks exist for ulipristal acetate emergency contraception under 10,772,897?
For generic entry risk, the relevant question is whether an ANDA or 505(b)(2) pathway product’s intended use and labeling practice implicate the asserted method claims.
Risk channels for method-of-use patents
- Labeling and carve-outs: Even if a generic has identical tablet strength, risk can hinge on whether the proposed labeling includes the “within 120 hours” and/or “more than 72 to 120 hours” instructions, and whether it supports repeat dosing at least twice in a menstrual cycle.
- Carve-out effectiveness: A generic can mitigate risk only if it meaningfully carves out the method practice covered by the claims.
Likely infringement posture in litigation
- Litigation on method-of-use patents generally centers on inducement and use-based practice. Marketing that encourages administration into the claimed window can trigger infringement theories even if generics do not control actual patient dosing.
How does FDA regulatory status and Orange Book listing affect whether 10,772,897 blocks generic competition?
Whether 10,772,897 is listed in the FDA Orange Book for specific ulipristal acetate products is not derivable from the claim excerpt. Orange Book listings require patent number-to-NDA/NDC mapping, which is not provided.
Accordingly, no Orange Book status, listed use code, or trigger for 30-month stay can be stated here.
What patent litigation affects US 10,772,897?
Litigation events (complaints, stipulations, settlements, and claim construction outcomes) require docket records and PACER/RECAP-level details. Those are not provided in the prompt; therefore no accurate litigation impact analysis can be produced.
Claim-by-claim technical scope: what must an accused tablet and regimen do?
Claim 1 checklist
An accused method must include all of:
- Administering ulipristal acetate tablets
- containing 20 mg to 30 mg ulipristal acetate
- for contraception (emergency contraception context)
- to a woman
- within 120 hours after unprotected intercourse
Claim 2 checklist
Everything in claim 1 plus:
- dosing occurs more than 72 hours and up to 120 hours
Claim 3 checklist
Everything in claim 1 plus:
- administration is repeated at least twice during a menstrual cycle
Claim 4 checklist
Everything in claim 1 plus:
Claim 5 checklist
Everything in claim 1 plus:
- tablet is immediate-release oral
Key Takeaways
- US 10,772,897 protects a method of emergency contraception using 20–30 mg ulipristal acetate administered within 120 hours after unprotected intercourse.
- The claim set narrows on: 72–120 hour administration (claim 2), repeat dosing at least twice per menstrual cycle (claim 3), and oral immediate-release tablet format (claims 4–5).
- The highest-risk design-around levers are dose range, maximum timing window, dosing schedule, and dosage form/release type.
- Enforceability timelines, Orange Book status, and litigation outcomes cannot be determined from claim text alone.
FAQs
What is the key limitation in US 10,772,897 that most affects infringement?
The defining limitation is administering a tablet with 20–30 mg ulipristal acetate within 120 hours after unprotected intercourse.
Does US 10,772,897 require immediate-release for infringement?
Immediate-release is required for dependent claim 5. Claim 1 itself does not expressly require immediate-release.
How does the 72–120 hour window change the risk profile?
It specifically adds coverage in claim 2 for administration more than 72 up to 120 hours, which can be relevant if an accused product or labeling emphasizes later presentation.
Can a different ulipristal acetate strength avoid claim 1?
Avoiding the 20–30 mg tablet dose range is the primary direct route to avoid claim 1’s core limitation.
What does “repeated at least twice during a menstrual cycle” mean for scope?
It adds a regimen element for claim 3, requiring multiple administrations within one menstrual cycle, while still anchored to the emergency contraception method framework of claim 1.
References
- United States Patent 10,772,897 (claims provided in prompt).
